Vu Trang T, Leslie Beverly A, Stafford Alan R, Zhou Ji, Fredenburgh James C, Weitz Jeffrey I
Jeffrey Weitz, Thrombosis and Atherosclerosis Research Institute, 237 Barton St. E, Hamilton, Ontario L8L 2X2, Canada, Tel.: +1 905 521 2100 ext 40721, Fax: +1 905 575 2646, E-mail:
Thromb Haemost. 2016 Jan;115(1):89-98. doi: 10.1160/TH15-04-0336. Epub 2015 Sep 10.
When triggered by factor (F) XII and nucleic acids, we showed that thrombosis in HRG-deficient mice is accelerated compared with that in wild-type mice. In this study, we set out to identify the mechanisms by which nucleic acids promote contact activation, and to determine whether HRG attenuates their effects. DNA or RNA addition to human plasma enhances thrombin generation via the intrinsic pathway and shortens the clotting time. Their effect on the clotting time is seven- to 14-fold greater in HRG-deficient plasma than in control plasma. Investigations into the mechanisms of activation reveal that nucleic acids a) promote FXII activation in the presence of prekallikrein- and high molecular weight kininogen (HK), and b) enhance thrombin-mediated FXI activation by 10- to 12-fold. Surface plasmon resonance studies show that DNA and RNA bind FXII, FXIIa, HK, FXI, FXIa and thrombin with high affinity. HRG attenuates DNA- and RNA-mediated FXII activation, and FXI activation by FXIIa or by thrombin, suggesting that HRG down regulates the capacity of DNA and RNA to activate the intrinsic pathway. Therefore, HRG attenuates the procoagulant activity of nucleic acids at multiple levels.
当由因子(F)XII和核酸触发时,我们发现与野生型小鼠相比,HRG缺陷型小鼠的血栓形成加速。在本研究中,我们着手确定核酸促进接触激活的机制,并确定HRG是否减弱其作用。向人血浆中添加DNA或RNA可通过内源性途径增强凝血酶生成并缩短凝血时间。它们对凝血时间的影响在HRG缺陷型血浆中比在对照血浆中高7至14倍。对激活机制的研究表明,核酸a)在存在前激肽释放酶和高分子量激肽原(HK)的情况下促进FXII激活,并且b)将凝血酶介导的FXI激活增强10至12倍。表面等离子体共振研究表明,DNA和RNA以高亲和力结合FXII、FXIIa、HK、FXI、FXIa和凝血酶。HRG减弱DNA和RNA介导的FXII激活以及FXIIa或凝血酶介导的FXI激活,表明HRG下调DNA和RNA激活内源性途径的能力。因此,HRG在多个水平上减弱核酸的促凝血活性。